Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta‐Analysis
Journal of Medical Imaging and Radiation Oncology · 2026
DOI: 10.1111/1754-9485.70131 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2026. Verfasst von Zhao Feng Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Alfred Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Brain Neoplasms, Cranial Irradiation, Lung Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Prophylactic cranial irradiation (PCI) has traditionally been a cornerstone of treatment in limited‐stage and extensive‐stage small cell lung cancer (SCLC). Recent evidence suggests that active MRI brain surveillance may result in comparable overall survival (OS) and progression‐free survival (PFS). This systematic review and meta‐analysis aims to compare patient outcomes between PCI and active MRI brain surveillance.
Method
Medline, Embase, Cochrane Library, Scopus and Web of Science databases were searched from inception until 30th April 2025 to identify all studies comparing PCI against active MRI brain surveillance in adult SCLC patients. Risk ratios (RR) and hazard ratios (HR) were pooled and analysed using a random‐effects model.
Result
Fourteen studies comprising 2881 patients were included. In patients with limited‐stage SCLC, PCI significantly improved OS (HR 0.67, 95% CI 0.53–0.84, p < 0.01), PFS (HR 0.77, 95% CI 0.65–0.91, p < 0.01), and brain metastasis (BM) incidence (RR 0.58, 95% CI 0.45–0.76, p < 0.01). In patients with extensive‐stage SCLC, PCI only significantly reduced BM risk (RR 0.49, 95% CI 0.29–0.81, p < 0.05), but was not associated with significant improvement in OS (HR 0.89, 95% CI 0.61–1.28, p = 0.52) or PFS (HR 0.90, 95% CI 0.60–1.36, p = 0.62).
Conclusion
While PCI reduces BM incidence in both limited‐stage and extensive‐stage SCLC, its survival benefits are confined to limited‐stage SCLC. Active MRI brain surveillance may be preferred in extensive‐stage disease due to comparable survival outcomes and reduced toxicity. Trial Registration CRD42024529707 [PROSPERO]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Alfred Hospital, Melbourne, Victoria, Australia.
- Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Hudson Institute for Medical Research, Clayton, Victoria, Australia.
- Faculty of Medicine, Monash University, Clayton, Victoria, Australia.
- Trans-Tasman Radiation Oncology Group, Newcastle, New South Wales, Australia.
ORCID-Profile: Zhao Feng Liu
Zitieren
APA
Liu, Z. F., Sylivris, A., Lin, Y. H., Ward, J., Cheng, M., Tham, J., D'Adamo, G., & Senthi, S. (2026). Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta‐Analysis. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.70131
Vancouver
Liu ZF, Sylivris A, Lin YH, Ward J, Cheng M, Tham J, et al. Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta‐Analysis. Journal of Medical Imaging and Radiation Oncology. 2026. doi:10.1111/1754-9485.70131
BibTeX
@article{Liu2026,
author = {Liu, Zhao Feng and Sylivris, Amy and Lin, Yuan-Hong and Ward, Jennifer and Cheng, Marcus and Tham, Jodie and D'Adamo, Gemma and Senthi, Sashendra},
title = {Prophylactic Cranial Irradiation Versus Active MRI Surveillance in Small Cell Lung Cancer: Systematic Review and Meta‐Analysis},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2026},
doi = {10.1111/1754-9485.70131}
}
EUVIMED